{"url_path":"/sec/slno/8-k/2026-05-18/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","accession_number":"0001193125-26-228016","cik":"0001484565","ticker":"SLNO","issuer_name":"SOLENO THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","primary_entity_key":"0001484565","primary_entity_name":"SOLENO THERAPEUTICS INC"},"word_count":187,"has_tables":true,"body_markdown":"Item 1.02.\n\nTermination of a Material Definitive Agreement\n\nOn May 18, 2026, in connection with the Merger, the Company, as borrower, terminated the Loan and Security Agreement, dated as of December 17, 2024, as amended, by and among the Company, Essentialis, Inc., the lenders from time to time party thereto and Oxford Finance LLC, as collateral agent (the “Loan and Security Agreement”). The Company previously filed the Loan and Security Agreement as Exhibit 10.16 to its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 28, 2025.\n\n \n\nEmployee Stock Purchase Plan\n\nIn accordance with the terms of the Merger Agreement, effective immediately prior to the Effective Time, the Company terminated its 2014 Employee Stock Purchase Plan (the “ESPP”). The Company previously filed the ESPP as Exhibit 10.5 to its Registration Statement on Form S-1, as amended (File No. 333-196635), originally filed with the SEC on July 1, 2014, and declared effective on November 12, 2014.\n\nThe information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 1.02."}